|
gptkbp:instanceOf
|
gptkb:antibiotic
rifamycin
|
|
gptkbp:affiliatedWith
|
ansamycins
|
|
gptkbp:ATCCode
|
J04AB01
|
|
gptkbp:brand
|
Eremfat
Rifamycin-Na
|
|
gptkbp:CASNumber
|
14897-39-3
|
|
gptkbp:chemicalFormula
|
C37H47NO12
|
|
gptkbp:derivedFrom
|
gptkb:Amycolatopsis_mediterranei
|
|
gptkbp:discoveredBy
|
gptkb:Piero_Sensi
F. Bordoni
G. Lancini
G. Parenti
Gabriele Somma
|
|
gptkbp:discoveredIn
|
1957
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Rifamycin SV
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Italy
|
|
gptkbp:mechanismOfAction
|
inhibits DNA-dependent RNA polymerase
|
|
gptkbp:meltingPoint
|
>200°C
|
|
gptkbp:molecularWeight
|
701.76 g/mol
|
|
gptkbp:origin
|
fermentation product
|
|
gptkbp:relatedTo
|
gptkb:rifampicin
gptkb:rifabutin
rifapentine
|
|
gptkbp:routeOfAdministration
|
oral
topical
|
|
gptkbp:sideEffect
|
allergic reactions
liver toxicity
gastrointestinal upset
|
|
gptkbp:solubility
|
slightly soluble in water
|
|
gptkbp:UNII
|
QZJ8J8U5F4
|
|
gptkbp:usedFor
|
treatment of bacterial infections
treatment of tuberculosis
treatment of leprosy
|
|
gptkbp:bfsParent
|
gptkb:RV_717
|
|
gptkbp:bfsLayer
|
7
|